Sanjeev Jha*, Ravikant Kumar, Saurabh Kumar, Ravi Keshri, Aditya V. Singh, Gaurav Kumar and Samir S. Bhagwat
Background: The effect of Tenofovir Alafenamide (TAF) therapy on viral suppression and hepatic function in patients of Hepatitis B Virus (HBV) related decompensated cirrhosis is not known. Aim of this study was to evaluate the efficacy and safety of TAF therapy in these patients.
Methods: We analyzed 55 consecutive HBV-infected treatment naive patients with decompensated cirrhosis treated with 25 mg/day TAF and evaluated the treatment outcomes. Treatment efficacy was evaluated by measuring virological, serological, biochemical responses and changes in hepatic function over period of 6 month.
Results: At month 6, undetectable HBV-DNA level, HBeAg loss, HBeAg seroconversion and ALT normalization was seen in 65.2%, 22.2%, 5.5% and 74.5% patients respectively. Virological and biochemical responses were similar in HBeAg positive and negative patients. CTP (8.38 ± 1.56 vs. 6.73 ± 1.05), MELD-Na (16.00 ± 6.22 vs. 12.00 ± 4.50), bilirubin [1.65 (0.4-16.7) mg/dL vs. 1.20 (0.7-3.2) mg/dL], INR (1.45 ± 0.35 vs. 1.32 ± 0.32), albumin (2.88 ± 0.58 vs. 3.05 ± 0.39 g/dL), and ALT (68 IU/L (19-390) vs. 36 IU/L (11-94)) was significantly improved after 6 months of TAF treatment. 45.5% and 47.2% patients showed improvement in CTP and MELD-Na score by ≥ 2 points after 6 months. There was no significant difference in eGFR measured respectively at baseline and at month 6 (94.82 ± 38.66 vs. 92.93 ± 25.75 mL./minute, p=0.64).
Conclusion: TAF therapy is effective in decreasing HBV DNA levels, normalizing ALT, improving hepatic function and is well tolerated in decompensated cirrhosis patients.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 